These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

697 related items for PubMed ID: 15944776

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [Abstract] [Full Text] [Related]

  • 23. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
    Duffy MJ.
    Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
    [Abstract] [Full Text] [Related]

  • 24. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [Abstract] [Full Text] [Related]

  • 25. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA, Leaper DJ, Hayter JP, Dickenson AJ.
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [Abstract] [Full Text] [Related]

  • 26. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, Podgorniak MP, Labarchède G, Lebbé C, Calvo F, Menashi S, Mourah S.
    Cancer Res; 2007 Jan 01; 67(1):9-15. PubMed ID: 17210677
    [Abstract] [Full Text] [Related]

  • 27. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L, Han X.
    Biomed Pharmacother; 2013 Mar 01; 67(2):179-82. PubMed ID: 23201006
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N, Thomssen C.
    Zentralbl Gynakol; 2003 Sep 01; 125(9):362-7. PubMed ID: 14569518
    [Abstract] [Full Text] [Related]

  • 30. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y.
    Anticancer Res; 2000 Sep 01; 20(5A):3031-6. PubMed ID: 11062719
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F.
    Pathol Biol (Paris); 2000 Nov 01; 48(9):825-31. PubMed ID: 11141918
    [Abstract] [Full Text] [Related]

  • 34. Markers of the uPA system and common prognostic factors in breast cancer.
    Minisini AM, Fabbro D, Di Loreto C, Pestrin M, Russo S, Cardellino GG, Andreetta C, Damante G, Puglisi F.
    Am J Clin Pathol; 2007 Jul 01; 128(1):112-7. PubMed ID: 17580278
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
    Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J, Bobin JY.
    Clin Breast Cancer; 2008 Apr 01; 8(2):168-77. PubMed ID: 18621614
    [Abstract] [Full Text] [Related]

  • 38. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.
    Cancer Res; 1994 Oct 15; 54(20):5445-54. PubMed ID: 7923178
    [Abstract] [Full Text] [Related]

  • 39. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
    Choong PF, Nadesapillai AP.
    Clin Orthop Relat Res; 2003 Oct 15; (415 Suppl):S46-58. PubMed ID: 14600592
    [Abstract] [Full Text] [Related]

  • 40. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
    Ruppert C, Ehrenforth S, Scharrer I, Halberstadt E.
    Cancer Detect Prev; 1997 Oct 15; 21(5):452-9. PubMed ID: 9307848
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.